ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
IPO Year:
Exchange: NYSE
Website: resmed.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/24/2024 | $280.00 | Outperform | Robert W. Baird |
| 9/18/2024 | $180.00 | Peer Perform → Underperform | Wolfe Research |
| 9/4/2024 | Buy → Hold | Needham | |
| 6/25/2024 | Outperform → Perform | Oppenheimer | |
| 6/24/2024 | Buy → Neutral | Citigroup | |
| 2/6/2024 | $227.00 | Overweight | KeyBanc Capital Markets |
| 10/27/2023 | $180.00 → $169.00 | Equal-Weight → Overweight | Morgan Stanley |
| 10/12/2023 | $273.00 → $202.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 10/9/2023 | $210.00 → $170.00 | Neutral → Overweight | JP Morgan |
| 9/29/2023 | Outperform → Peer Perform | Wolfe Research |
Issued on behalf of Avant Technologies Inc. USA News Group News Commentary VANCOUVER, BC, Nov. 12, 2024 /PRNewswire/ -- Recently the World Economic Forum released a report that highlights AI's potential to relieve pressure on healthcare systems worldwide, with Mayo Clinic's early adoption showing how AI can drive progress. Elon Musk has also hinted that his company's Grok AI could have applications in medical image analysis. At this year's HLTH conference in Las Vegas, tech giants like Nvidia, Google, and Microsoft presented their latest AI healthcare tools. Meanwhile, a range of emerging tech companies are making strides in AI-powered healthcare, including: Avant Technologies, Inc. (OTCQB:
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Palos Verdes, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following t
Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%Operating cash flow of $326 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended September 30, 2024. First Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 11% to $1.2 billion; up 11% on a constant currency basis Gross margin improved 420 bps to 58.6%; non-GAAP gross margin improved 320 bps to 59.2%Income from operations increased 34%; non-GAAP income from operation
SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: http://investor.resmed.com Date: Thursday, October 24, 2024 Time: 1:30 p.m. PDT / 4:30 p.m. EDT International: London, Thursday, October 24, 2024, 9:30 p.m. BSTSydney, Friday, October 25, 2024, 7:30 a.m.
2030 ambition to help more than 500 million people worldwide achieve their full health potentialShowcases integration of intelligent products and solutions within the ResMed ecosystem, designed to deliver a better experience, lower costs, and enhanced outcomes for patients and providersIntroduces updated five-year financial outlook NEW YORK and SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today unveiled its 2030 Strategy to drive growth, profitability, and shareholder returns at an Investor Day in New York City. ResMed also announced its five-year revenue and earnings growth outlook, reflecting ResMed's plans to accelerate product and technology innova
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))), the world's leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ResMed first in CPAP (continuous positive airway pressure) mask innovation with the launch of the AirTouch™ N30i. Designed to create a natural and comfortable sleep experience for users, the AirTouch N30i is a fabric-wrapped frame featuring a soft, breathable, and moisture-wicking design for optimal comfort in a tube-up design. Sleep apnea affects more than 54 million people in the United States and nearly one billion people worldwide1. This chronic sleep-related breathing disorder can
ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir™ consumer app with Apple and Android smartwatches. Introduces a Generative AI-enabled sleep health assistant to guide people on their journey to better sleep and new travel gear to help people stay on CPAP treatment while traveling. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))), the world's leading health technology company focused on sleep, breathing, and care delivered in the home, today announced new patient-centric products designed to enhance the therapy journey for sleep apnea patients. These i
Learn more about ResMed's 2030 strategy to accelerate growthJoin in person or via virtual webcast SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) will host an investor day on Monday, September 30, 2024, beginning at approximately 1:00 p.m. (Eastern Daylight Time). As previously announced, the event will be held at the New York Stock Exchange in New York City and simultaneously webcast online. More information about this event, including access to the live webcast link (available soon) and an RSVP link to request to attend the event in person, may be accessed by visiting https://investor.resmed.com. The webcast replay will be available shortly after the
New ResMed-supported research presented at ERS 2024 projects future Chronic Obstructive Pulmonary Disease (COPD) burden in Western Europe, accounting for increased air pollution, tobacco smoking, and vaping, with Non-Invasive Ventilation (NIV) enhancing survival rates. 88.7 million new COPD hospitalizations projected across Western Europe between 2019 - 2050Vaping projected to incur almost €30 billion additional direct and indirect costs by 2050€4.9 trillion projected cumulative cost to support COPD lung conditions by 205016% projected reduction in risk of death after a severe exacerbation for COPD patients using home NIV support SAN DIEGO and VIENNA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- R
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, beginning at approximately 10:00 a.m. (Eastern Daylight Time) at the New York Marriott Marquis in New York, NY. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible f
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs cut the price target for SunPower Corporation (NASDAQ:SPWR) from $2 to $0.5. Goldman Sachs analyst Brian Lee maintained a Sell rating. SunPower shares gained 5.4% to close at $0.7158 on Monday. See how other analysts view this stock. Piper Sandler increased the price target for Cathay General Bancorp (NASDAQ:CATY) from $32 to $36. Piper Sandler analyst Matthew Clark maintained an Underweight rating. Cathay General Bancorp shares gained 2.4% to close at $43.02 on Monday. See how other
During the last three months, 6 analysts shared their evaluations of ResMed (NYSE:RMD), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 2 0 0 Last 30D 0 0 1 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 2 1 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $219.0, with a high estimate of $238.00 and a low estimate of $200.00. This upward trend is apparent, with the
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $200 to $204.
ResMed's (NYSE:RMD) short percent of float has fallen 16.56% since its last report. The company recently reported that it has 8.24 million shares sold short, which is 6.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.87 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is impo
ResMed (NYSE:RMD) has outperformed the market over the past 15 years by 3.3% on an annualized basis producing an average annual return of 16.26%. Currently, ResMed has a market capitalization of $27.63 billion. Buying $1000 In RMD: If an investor had bought $1000 of RMD stock 15 years ago, it would be worth $9,562.07 today based on a price of $188.10 for RMD at the time of writing. ResMed's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume PFE CALL SWEEP BEARISH 07/19/24 $28.00 $74.9K 29.5K 5.7K ZTS CALL SWEEP BEARISH 07/19/24 $170.00 $39.
Analysts' ratings for ResMed (NYSE:RMD) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 1 0 0 Last 30D 0 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 2 1 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for ResMed, revealing an average target of $222.33, a high estimate of $238.00, and a low estimate of $200.00. Surpassing the previous average
Oppenheimer analyst Suraj Kalia downgrades ResMed (NYSE:RMD) from Outperform to Perform.
ResMed, Inc. (NYSE:RMD) stock is trading lower Monday after Eli Lilly and Company (NYSE:LLY) released data from a clinical trial in regards to the treatment of sleep apnea. The Details: Lilly released data on Friday from its SURMOUNT-OSA phase 3 clinical trial which tested tirzepatide as a treatment for obstructive sleep apnea. This could present a potential competitive headwind for ResMed, which develops flow generators, masks and accessories for the treatment of sleep apnea. The trial evaluated the treatment at two dosage levels, 10 mg and 15 mg. Tirzepatide achieved all primary and secondary endpoints related to efficacy and treatment regimen. In the primary endpoint, the treatme
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday. Shares of ResMed Inc. (NYSE:RMD) fell sharply during Monday's session following sleep apnea data from Lilly. Citigroup analyst Mathieu Chevrier downgraded ResMed from Buy to Neutral. ResMed shares dipped 10.4% to $184.35 on Monday. Here are some other big stocks recording gains in today’s session. Molecular Partners AG (NASDAQ:MOLN) shares dipped 22.6% to $7.43. Cryoport, Inc. (NASDAQ:CYRX) fell 19.9% to $7.77. Cryoport announced a strategic partnership with Minaris Regenerative Medicine for cell and gene therapies advancement. BridgeBio Pharma, Inc. (NASDAQ:BBIO) dipped 19.2% to $22.1
Robert W. Baird initiated coverage of ResMed with a rating of Outperform and set a new price target of $280.00
Wolfe Research downgraded ResMed from Peer Perform to Underperform and set a new price target of $180.00
Needham downgraded ResMed from Buy to Hold
Oppenheimer downgraded ResMed from Outperform to Perform
Citigroup downgraded ResMed from Buy to Neutral
KeyBanc Capital Markets resumed coverage of ResMed with a rating of Overweight and set a new price target of $227.00
Morgan Stanley upgraded ResMed from Equal-Weight to Overweight and set a new price target of $169.00 from $180.00 previously
RBC Capital Mkts downgraded ResMed from Outperform to Sector Perform and set a new price target of $202.00 from $273.00 previously
JP Morgan upgraded ResMed from Neutral to Overweight and set a new price target of $170.00 from $210.00 previously
Wolfe Research downgraded ResMed from Outperform to Peer Perform
8-K - RESMED INC (0000943819) (Filer)
DEFA14A - RESMED INC (0000943819) (Filer)
10-Q - RESMED INC (0000943819) (Filer)
8-K - RESMED INC (0000943819) (Filer)
DEFA14A - RESMED INC (0000943819) (Filer)
DEF 14A - RESMED INC (0000943819) (Filer)
8-K - RESMED INC (0000943819) (Filer)
10-K - RESMED INC (0000943819) (Filer)
8-K - RESMED INC (0000943819) (Filer)
SD - RESMED INC (0000943819) (Filer)
Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%Operating cash flow of $326 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended September 30, 2024. First Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 11% to $1.2 billion; up 11% on a constant currency basis Gross margin improved 420 bps to 58.6%; non-GAAP gross margin improved 320 bps to 59.2%Income from operations increased 34%; non-GAAP income from operation
SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: http://investor.resmed.com Date: Thursday, October 24, 2024 Time: 1:30 p.m. PDT / 4:30 p.m. EDT International: London, Thursday, October 24, 2024, 9:30 p.m. BSTSydney, Friday, October 25, 2024, 7:30 a.m.
Year-over-year revenue grows 9%, operating profit up 38%, non-GAAP operating profit up 30%Operating cash flow of $440 millionQuarterly dividend increases 10% to $0.53 per shareCompany to host an Investor Day on September 30, 2024 Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended June 30, 2024. Fourth Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 9% to $1.2 billion; up 10% on a constant currency basis Gross margin improved 350 bps to 58.5%; non-GAAP gross ma
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2024 on Thursday, August 1, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: http://investor.resmed.com Date: Thursday, August 1, 2024 Time: 1:30 p.m. PDT / 4:30 p.m. EDT International: London, Thursday, August 1,
Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23%Operating cash flows of $402 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended March 31, 2024. Third Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 7% to $1.2 billion; up 7% on a constant currency basis Gross margin grew 260 bps to 57.9%; non-GAAP gross margin grew 240 bps to 58.5%Income from operations increased 25%; non-GAAP operating profit u
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:http://investor.resmed.com • Date:Thursday, April 25, 2024 • Time:1:30 p.m. PDT / 4:30 p.m. EDT • International:London, Thursday, April 25, 2024, 9:30 p.m. BSTSydney, Friday, April 26, 2024, 6:30 a.m. AEST Please note, ResM
Year-over-year revenue grows 12%, operating profit down 2%, non-GAAP operating profit up 20%Resumed share repurchase program, repurchased $50 million during quarter Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended December 31, 2023. Second Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 12% to $1.2 billion; up 11% on a constant currency basis Gross margin contracted 50 bps to 55.6%; non-GAAP gross margin grew 10 bps to 56.9%Income from operations decreased 2
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on Wednesday, January 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:http://investor.resmed.com• Date:Wednesday, January 24, 2024• Time:1:30 p.m. PST / 4:30 p.m. EST• International:London, Wednesday, January 24, 2024, 9:30 p.m. GMT Sydney, Thursday, January 25, 2024, 8:30 a.m. AEDT Please
Year-over-year revenue grows 16%, operating profit up 5%, non-GAAP operating profit up 10%Expects to resume its share repurchase program during upcoming quarter Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended September 30, 2023. First Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 16% to $1.1 billion; up 15% on a constant currency basis Gross margin contracted 250 bps to 54.4%; non-GAAP gross margin contracted 160 bps to 56.0%Income from operations increas
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it plans to release financial and operational results for the first quarter of fiscal year 2024 on Thursday, October 26, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:http://investor.resmed.com•Date:Thursday, October 26, 2023•Time:1:30 p.m. PDT / 4:30 p.m. EDT•International:London, Thursday, October 26, 2023, 9:30 p.m. BSTSydney, Friday, October 27, 2023, 7:30 a.m. AEDT Please note, ResM
DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the worldBoard appointment brings over 30 years of strategic and operational finance expertise SAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed's regularly scheduled board meeting on August 15, 2024, and will stand for re-election with the rest of ResMed's directors at its annual meeting on November 21, 2024. Mr. DelOrefice has also been appointed as a member of ResMed's board au
Rider and Haake, both internal promotions, joined ResMed's executive team on May 1Rider, currently Senior Vice President, Deputy Global General Counsel will succeed retiring Chief Administrative Officer, Global General Counsel, and Secretary David Pendarvis on July 1 SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced the appointment of two new executive team members: Michael Rider, Global General Counsel & Secretary, effective July 1, 2023, and Dawn Haake as ResMed's first Chief Quality Officer, effective May 1, 2023. Both joined ResMed's executive team on May 1 and report to the Office of the CEO. Michael Rider was selected following a previously a
SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced ResMed's board of directors has appointed chief executive officer Michael ("Mick") Farrell as chair of the board, effective January 25, 2023. Mr. Farrell succeeds current chair Peter Farrell who will become chair emeritus and will remain an active board member. Mick Farrell became ResMed's CEO on March 1, 2013, and has served as a member of the company's board of directors since assuming that role. "I am honored to expand my role with ResMed as its next chair and to succeed my dad, Peter Farrell, whose vision, leadership, and guidance have helped ResMed become the largest outside-hospital, digital
Tyagi brings over 25 years' IT and leadership experience from ADP, American Express, Amazon, Microsoft, and IBMCurrent CTO and SaaS President Bobby Ghoshal now transitions to SaaS full-time SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced the appointment of Urvashi Tyagi as chief technology officer (CTO), effective today. As CTO, Tyagi will lead ResMed's Digital Health Technology team, driving the innovation and adoption of its world-leading cloud-based digital health platforms, as well as investments in emerging technologies like artificial intelligence and machine learning. Tyagi has over 25 years' experience in IT and mechanical enginee
Renowned MedTech leaders join EBR Board of Directors Highlights: Dr Evans, Dr Steinhaus and Ms Drexler to join EBR Systems' Board ahead of the planned A$110m IPO on the Australian Stock Exchange Board appointments follow the retirement of Mr Dave Stassen and Dr Leighton Read New EBR Systems' Board consists of Mr Allan Will, Mr John McCutcheon, Dr Christopher Nave, Mr Trevor Moody, Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler EBR Systems, Inc., developer of the world's only wireless cardiac pacing system for heart failure, today announced the appointment of Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler to the Board as Independent Non-Executive Directors. D
PRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that it has appointed Jan D. De Witte as its next President and Chief Executive Officer. Mr. De Witte succeeds Peter J. Arduini, who previously announced he will step down as Chief Executive Officer to accept the role of President and Chief Executive Officer of GE Healthcare. Mr. De Witte will join Integra prior to the end of the year, at which time he will also be appointed to Integra's board of directors. With over two decades in the healthcare industry, De Witte brings global public company leadership experience as well
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, is bolstering its board of directors with the appointment of Karen Drexler. Drexler currently serves on the boards of ResMed (NYSE: RMD), a $31B data-driven sleep and respiratory market leader; VIDA Diagnostics, developer of AI-powered lung intelligence and imaging solutions; and Tivic Health, a bioelectronic medicine company. Named one of Women Inc. magazine’s most influential corporate directors in 2018, Drexler brings to Outset a deep understanding of how to utilize data analytics and mac
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rajwant (Raj) Singh Sodhi as an independent member of its board of directors effective January 1, 2021. He will succeed Edward Cahill, who has served as a board member for the Company since May 2009. Mr. Sodhi is president of the software as a service (SaaS) business at ResMed (NYSE: RMD, ASX: RMD). He brings to the Tandem board more than 25 years of digital strategy experience, SaaS commercialization and operations across multiple industries including healthcare, financial services, and telecom. “We are pleased to w